Clin Osteol 2003; 8(3): 82-85

Monitoring the skeletal effects of estrogens and tibolonArticles

J. Vokrouhlická

Long-term use of hormone replacement therapy (HRT) is associated with a significant reduction of vertebral and non-vertebral fracture risk in post­ menopausal women. HRT reduces bone turnover into premenopausal range and in a dose-response relationship gradually increases bone mass. For a 90% sensitivity to predict a positive bone mineral density (BMD) response cut-off values of bone markers, expressed as a percentage decrease from baseline, are: -45 % for urinary telopeptides, -35 % for serum CTX, -20 % for urinary deoxypyridinoline, -20 % for serum osteocalcin or bone ALP. Ta­ king into account the least significant change (LSC) of the DEXA machine and th lead to an reevaluation of an inadequate response of skeleton to the treatment. Tibolone is the only representative of a separate class of compounds classified as STEARs (selective tissue estrogenic activity regulators). The action of tibolone on bone is clearly estrogen-like effect. Tibolone and estrogens have comparable effects on bone markers and BMD, however fracture data with tibolone are not yet available and there are currently no recommendations for m

Keywords: hormone replacement therapy, tibolone-monitoring of the skeletal effects.

Published: December 11, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vokrouhlická J. Monitoring the skeletal effects of estrogens and tibolon. Osteologický bulletin. 2003;8(3):82-85.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Štěpán JJ, Pospíchal J, Presl J, et al. Prospective trial of ossein-h compound (OHC) in surgically induced postmenopausal women. Bone 1989;10: 179-85. Go to original source...
    2. Khastgir G, Studd J, Holland A et al. Anabolic effect of estrogen repla bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study. JCEM 2001;86:289-95. Go to original source...
    3. Štěpán JJ, Pospíchal J, Schreiber V, et al. The application of plasma tartrate re stant acid phosphatase to assess changes in bone resorption to artificial menopau­ se and its treatment with estrogen and norethisterone. Calcif Tissue Int 1989;46: 273-80. Go to original source...
    4. Delmas PI, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int 2000;(Suppl6):2-17. Go to original source...
    5. PEPI (Writing Group for Postmenopausal Estrogen/Progestin Interventions Trial). Effects of hormone therapy on bone mineral density. Results from the postmeno­ pausal estrogen/progestin interventions [PEPI] trial. J Am Med Assoc 1996;276: 1389-96. Go to original source...
    6. Wells G, Tugwell P, Shea B, et al. Meta-analysis of the efficacy of hormone re­ placement therapy in treating and preventing osteoporosis in postmenopausal wo­ men. Edocrine Rev 2002;23:529-39. Go to original source...
    7. Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continu­ ous estrogen and progesterone therapy with calcium and vitamin D on bone in el­ derly women. Ann Intern Med 1999;130:897-904. Go to original source...
    8. Ettinger B, Genant HK, Steiger P, et al. Low-dose micronized 17-estradiol pre­ vents bone loss in postmenopausal women. Amer J Obstet Gynecol 1992;166: 479-88. Go to original source...
    9. Notelovitz M, Johnston M, Smith S, et al. Metabolic and hormonal effects of 25­ mg and 50-mg 17p-estradiol implants in surgically menopausal women. Obstet Gynecol 1987;70:749-54. Go to original source...
    10. Nieves JW, Komar L, Cosman F, Lindsay R. Calcium potentiates the effect of esterogen and calcitonin on bone mass: review and analysis. Am J Clin Nut. 1998;67: 18-24. Go to original source...
    11. Trémollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement the­ rapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporosis Int. 2001;12:385-90. Go to original source...
    12. Štěpán J, Formánková J, Mašatová, et al. Porovnání účinnosti léčby 17p-estradiolem a kalcitoninem u žen s úbytkem kostní hmoty po menopauze. Čas lék čes 1997;136:242-8.
    13. Randell KM, Hokanen RJ, Kroger H, Saarikoski S. Does hormone-replacement therapy prevent fractures in early postmenopausal women? J Bone Miner Res 2002;17:528-33. Go to original source...
    14. WHI (Writing Group for Women's Health Initiative Investigators). Risks and be­ nefits of estrogen plus progestin in healthy postmenopausal women. Principal re­ sults from the women's health initiative randomized controlled study. J Am Med Assoc 2002;288:321-33. Go to original source...
    15. Cauley JA, Lucas FL, Kuller LH, et al. Bone mineral density and risk of breast cancer in older women. J Am Med Assoc 1996;276:1404-8. Go to original source...
    16. Hammar M, Christau S, Nathorst-Boos, et al. A double-blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gy­ naecol 1998; 105:904-911. Go to original source...
    17. J^lacios S, Menendez C, Jurado R et al. Changes in sex behaviour after meno­ pause: effects of tibolone. Maturitas 1996;23:55-62.
    18. Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin Drug In­ vest 2000;20:101-7. Go to original source...
    19. Volker W, Coelingh Bennink HJT, Helmond FA Effects of tibolone on the endo­ metrium. Climacteric 2001;4:203-8. Go to original source...
    20. Morris EP, Chong H, Robinson J et al. Effects on the lower genital tract of lone use for 8 years in postmenopausal women. Maturitas 2000;35(Suppl 1):50.
    21. Roux C, Pelissier C, Fechtenbaum J, et al. Randomized, double-masked, 2-year comparison of tibolone with 17p-estradiol and norenthindrone acetate in preven­ ting postmenopausal bone loss. Osteoporosis Int 2002;13:241-8. Go to original source...
    22. Gallagher JC, Baylink DJ, Freeman R, et al. Prevention of bone loss with ne in postmenopausal women: Results of two randomized, double-blind, placebocontrolled, dose-finding studies. J Clin Endocrinol Metab 2001;86:471. Go to original source...
    23. Rymer J, Robinson J, Fogelman I, Ten years of treatment with tibolone 2.5 mg ily: effects on bone loss in postmenopausal women. Climacteric 2002;5:309-26. Go to original source...
    24. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: Prevention of postmeno­ pausal bone loss in elderly women. J Clin Endocrinol Metab 1996;81:2419-22. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.